Umeå University seeks to appoint a new Director for MIMS, The Laboratory for Molecular Infection Medicine Sweden, who will lead MIMS from 2018 upon the retirement of the founding Director, Professor Bernt Eric Uhlin.
MIMS (www.mims.umu.se) is established in a multi-disciplinary and dynamic research environment with high quality, creativity and development potential. MIMS is embedded in the Swedish academic setting involving regular faculty members of the university and it is connected to Umeå Centre for Microbial Research (UCMR, www.ucmr.umu.se), a virtual research centre spanning two faculties, the Faculty of Medicine and the Faculty of Science and Technology. The research environment includes the adjacent university hospital, Umeå University hospital (www.vll.se/startsida/forskning-och-utveckling).
The aim of MIMS is to strengthen Swedish research and enhance the dynamics in the field of molecular medicine, by promoting career opportunities and training of young scientists using the European Molecular Biology Laboratory (EMBL, www.embl.org/) as model. MIMS group leaders are successfully using the available interdisciplinary approaches in studies of virulence mechanisms and host-pathogen interactions of different microorganisms causing infections and diseases: bacteria, viruses, and parasites. MIMS also provides support and opportunities for young Swedish clinicians to conduct research in collaboration with the multi-disciplinary and dynamic MIMS research environment.
MIMS is the Swedish node in The Nordic EMBL Partnership for Molecular Medicine (www.embl.de/research/partnerships/remote/nordic/index.html), an international research infrastructure network jointly established with EMBL and nodes in Sweden, Norway, Finland, and Denmark. It is promoting international recruitment of top young scientist and provides them with resources, excellent infrastructure and mentorship to conduct research at a high international level as evidenced by several recent discoveries published by MIMS scientists.
The MIMS Director provides strong, dynamic, innovative and clear leadership to this laboratory which is supported at the national level by major grants from the Swedish Research Council and the Knut and Alice Wallenberg Foundation.
The Director will place emphasis on international recruitment and the mentoring support of young scientists connected to MIMS as new Group Leaders. The Director is expected to actively promote and maximize the interactions and collaboration with EMBL and the other Nordic nodes in accordance with the aims of the partnership agreement.
The Director will play a key role in developing MIMS both as an internationally renowned research laboratory and as a national resource promoting fundamental and translational research in molecular infection medicine.
The appointment will include a generous start up package to enable the new Director to establish her/his own strong research program at MIMS.
Candidates for the position will be able to think strategically, be innovative, have a global mind-set, and be capable of providing leadership. Candidates will also show a clear commitment to a broad base of interdisciplinary research in life science, and in particular have a clear familiarity with international and emerging trends in molecular medicine. Strong candidates will have an outstanding personal track record of research and funding in any area of molecular infection medicine, in addition to having strong leadership capabilities and demonstrable experience of leading or promoting interdisciplinary work in life science. The appointee must hold a doctoral degree and will be required to have the skills necessary to serve as an academic leader.
To successfully attend to the duties as MIMS Director, the appointee must have good English skills. Proficiency in Swedish is useful, but not necessary.
A MIMS Director Recruitment Committee headed by Professor Carl-Henrik Heldin, the Chairman of the MIMS Executive Board, will perform initial evaluation of applications. After interviews and further assessment by the MIMS Executive Board, a recommendation will be forwarded to the Vice-Chancellor of Umeå University for final decision about appointment as Professor with duties in the Faculty of Medicine.
The assignment as Director will initially be appointed for a term of 6 years with possibility of renewal for a second term. The appointee will be expected to assume the position during 2018 or upon agreement.
All submissions will be kept strictly confidential.